SU 14813
/ Pfizer
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 28, 2026
Targeting WDR12 Unleashes T-Cell-Mediated Antitumor Activity in Melanoma by Destabilizing CD276.
(PubMed, Adv Sci (Weinh))
- "In vivo, WDR12 targeting sensitizes tumors to PD-1 blockade, and combined SU14813 and anti-PD-1 therapy produces superior antitumor efficacy. These results define a WDR12-CCT7-CD276 axis that sustains immune resistance in melanoma and nominate WDR12 inhibition with PD-1 blockade as a promising therapeutic strategy."
IO biomarker • Journal • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor • CD276 • CD8
1 to 1
Of
1
Go to page
1